TD Cowen analyst Michael Nedelcovych maintained a Buy rating on Novo Nordisk (NVO – Research Report) today. The company’s shares closed ...

Goldman Sachs analyst James Quigley maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK875.00.

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes ...

I’m not going to report record revenue, but it was nonetheless a robust year," CEO Bernard Arnault said during the earnings ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Health care, ride sharing, and the emerging world of YouTube entertainers are among industries leading investors have picked ...

reNEW, the Novo Nordisk Foundation Center for Stem Cell Medicine, was launched in January 2022 and it supports stem cell research across three international sites in Denmark, Australia ...

The new pan-European group of 73 regulators, companies and trial sites is backed by €66.8m in funding with a six-year goal.